Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for Pegunigalsidase Alfa for Treatment of Fabry Disease

Stock Information for Protalix BioTherapeutics Inc. (DE)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Protalix BioTherapeutics Inc. (DE)

Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU
PLX Investors Have Opportunity to Join Protalix BioTherapeutics, Inc. Fraud Investigation with the Schall Law Firm
Levi & Korsinsky Launches Fraud Investigation on Behalf of Protalix BioTherapeutics, Inc. (PLX) Shareholders
Chiesi Global Rare Diseases and Protalix Biotherapeutics Acknowledge CHMP Negative Opinion on Every Four Week Dosing Regimen of Elfabrio® (pegunigalsidase alfa) in the EU
Protalix BioTherapeutics to Present at Investor Summit Virtual

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.